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Abstract
Background: Since late March 2013, there has been another global health concern with a sudden wave of flu
infections by a novel strain of avian influenza A (H7N9) virus in China. To-date, there have been more than 100
infections with 23 deaths. It is more worrying as this viral strain has never been detected in humans and only been
found to be of low-pathogenicity. Currently, there are 3 effective neuraminidase inhibitors for this H7N9 virus strain,
i.e. oseltamivir, zanamivir, and peramivir. These drugs have been used for treatment of the H7N9 influenza in China.
However, how these inhibitors work and affect the binding cavity of the novel H7N9 neuraminidase in the
presence of potential mutations has not been disclosed. In our study, we investigate steric effects and
subsequently show the conformational restraints of the inhibitor-binding site of the non-mutated and mutated
H7N9 neuraminidase structures to different drug compounds.
Results: Combination of molecular docking and Molecular Dynamics simulation reveal that zanamivir forms more
favorable and stable complex than oseltamivir and peramivir when binding to the active site of the H7N9
neuraminidase. And it is likely that the novel influenza A (H7N9) virus adopts a higher probability to acquire
resistance to peramivir than the other two inhibitors. Conformational changes induced by the mutation R289K
causes loss of number of hydrogen bonds between the inhibitors and the H7N9 viral neuraminidase in 2 out of 3
complexes. In addition, our results of binding-affinity relationships of the 3 inhibitors with the viral neuraminidase
proteins of previous pandemics (H1N1, H5N1) and the current novel H7N9 reflected the extent of binding
effectiveness of the 3 inhibitors to the novel H7N9 neuraminidase.
Conclusions: The results are novel and specific for the A/Hangzhou/1/2013(H7N9) influenza strain. Furthermore,
the protocol could be useful for further drug-binding analysis and prediction of future viral mutations to which the
virus evolves through adaptation and acquires resistance to the current available drugs.
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Background
There has been another global health concern since the
last few months by the emergence of a novel strain of
avian influenza A (H7N9) virus, which has never been
detected in humans [1,2]. The virus has infected more
than 100 with 23 deaths as of April 16, 2013 [3].
According to World Health Organization (WHO), this
avian influenza A (H7N9) strain is considered to be one
of the most lethal influenza viruses [4] because reported
infections occur sporadically, and asymptomatically (i.e.
one patient case found in Beijing, China) [2]. This novel
low-pathogenic H7N9 strain does not cause disease
symptoms in animals; hence it easily escapes detection
from animal reservoir and has higher probability to
transmit than the previous highly pathogenic H5N1
strain, which killed hundreds worldwide [5,6]. Even
though there has been no epidemiological evidence of
direct transmission between humans, signs of viral adap-
tion to humans via its mutations have been detected
[7,8]. Therefore, it could be just a matter of time before
the new strain of virus can pose a potential human
pandemic.
Genetic analysis have shown that H7N9 virus could
acquire through adaptation the ability to infect mam-
mals (especially humans) better than other avian influ-
enza strains [1,9] via critical mutations [5,10]. The novel
H7N9 virus is known to be susceptible to neuraminidase
inhibitors oseltamivir and zanamivir. Recently, another
antiviral drug peramivir has been approved for H7N9
influenza treatment in China. These drug compounds
inhibit enzymatic activity of the viral neuraminidase,
which has a role in the final step of sialic acid cleavage
that helps release the virus from the infected cells [11].
Gene mutations that cause viral resistance to most of
the drugs have raised significant concern because they
may trigger potential pandemics. Typical well-established
mutation His274Tyr (N2 numbering) within the neura-
minidase (NA) has been known to confer a very high
level of resistance to oseltamivir without compromising
viral fitness in the highly pathogenic influenza viruses
(H5N1 and H1N1) of both the previous pandemics
[12-16]. Russell et al. found that there are substantial
conformational differences adjacent to the binding sites
between group-1 (N1, e.g. H5N1, H1N1) and group-2
(N9, e.g. H7N9) neuraminidases [15], causing this H274Y
mutation against oseltamivir to have little effect on N9
neuraminidase compared to the other NA group [15,16].
Instead, the novel H7N9 has acquired other gene muta-
tions to adapt itself more “human-like” [5,10]. In fact, all
H7N9 specimens in China show a deletion of five resi-
dues (position 69-73) in the viral NA stalk compared to
the avian-origin influenza A (H7N9) [17], and it was
once found to increase virulence in mice [18]. So far, a
gene mutation for Arg292Lys (R292K, N2 numbering)
found in the first case of H7N9 (/Shanghai/1/2013) in
China causes reduced drug susceptibility to oseltamivir
and zanamivir [17,19]. Interaction mechanism of the sub-
stituted residue Lys292 in the binding sites of some viral
N1 and N9 neuraminidases were investigated [15,20].
However, how this R292K (R289K in H7N9 numbering)
mutation affects the inhibitor-binding site of the novel
avian influenza A (H7N9) virus has not yet been under-
stood. Therefore, our work aims to provide an insight
into the conformational changes of the novel H7N9
neuraminidase binding site in the presence of the muta-
tion. With this, we hope to understand how these steric
changes affect bindings of the three inhibitors oseltami-
vir, zanamivir, and peramivir.
Results and discussion
Mutation R289K causes different conformational changes
in the structure of the H7N9 Neuraminidase when it
interacts with oseltamivir, zanamivir, and peramivir
We used 3 current approved neuraminidase inhibitors
(i.e. oseltamivir, zanamivir, and peramivir), which are
applied in the treatment of the influenza A (H7N9), to
dock independently as ligand to the non-mutated struc-
ture of the H7N9 neuraminidase (NA) using Autodock
4.2 [21]. Subsequently, we performed molecular
dynamics (MD) simulation using AMBER 11 [22] for
each complex of NA/inhibitor to obtain optimal bound
conformations (see Methods). As observed in our dock-
ing results, all the inhibitors bind to active site residues
of the H7N9 NA (Table 1). Among the 3 NA inhibitors,
zanamivir interacts more favorably with the H7N9 NA
than oseltamivir and peramivir since the complex of
NA/zanamivir obtains lower binding free energy (-54.73
kcal/mol) than complexes of the other two compounds
(-49.49 kcal/mol and -39.02 kcal/mol respectively)
(Table 2).
To detect how the conformation of the H7N9 NA
changes due to the mutation R289K and in the presence
of the inhibitors, we substituted the residue Lys (K) for
Arg (R) at the position 289 (292 in N2 numbering) using
DeepView v4.1 [23]. Minimization and 20-nanosecond
MD simulation were performed for the new mutated
NA/inhibitor complexes to reach the equilibrium states.
Our results indicate that the mutation R289K may result
in reducing the drug susceptibility of the viral strain
Table 1 Interactions between three NA inhibitors and the
H7N9 NA binding site residues
NA Inhibitor Non-mutated NA R289K-mutated NA #H-bond*
Oseltamivir Arg367, Glu422 Arg367, Glu422 2/2
Zanamivir Arg152, Glu422 Glu422, Lys289 4/3
Peramivir Glu274 Glu422 3/2
*numbers of hydrogen bond between the inhibitor and NA: before/after
mutation occurs
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A/Hangzhou/1/2013 (H7N9) to oseltamivir, zanamivir,
and peramivir. In fact, except for the case of NA/oselta-
mivir complex, losses of hydrogen bonds between the
inhibitors and the enzyme active sites due to R289K-
induced conformational changes of the NA structure are
observed (Table 1).
Structural comparisons between the non-mutated and
the mutated NA/inhibitor complexes reveal steric varia-
tions of the active site residues and the inhibitor-bound
orientations to explain various conformational adaptions
of the NA binding pocket in the presence of different inhi-
bitors. In the case of oseltamivir, mutation R289K does
not cause any hydrogen bond loss; however, according to
our hydrogen bond analysis (see Additional file 1), occur-
rence of the 2 hydrogen bonds (i.e. between the NA resi-
dues Arg367, Glu422 and the oseltamivir) decreases during
the 20ns MD simulation process. It suggests that oseltami-
vir may be losing contacts with the H7N9 NA during the
viral adaption. While the residue Arg289 interacts with
Glu274 and Glu273, the substituted smaller residue Lys289
interacts with Tyr401 and Glu273. This creates extra empty
space, which could be large enough for an interference of
the bulky residue Trp292; subsequently induces contacts
among other neighboring residues Trp292, Asn342, and
Thr11. These interactions change the conformations of the
enzyme N-terminus and surrounding residues, i.e. Gln5,
Thr144, and Ile145; consequently result in losing contacts
with oseltamivir (Figure 1A).
Similar to the case of oseltamivir, substitution of a smal-
ler residue Lys289 increases the empty space among resi-
dues surrounding the binding sites of the NA/peramivir
complex. In this mutated complex, peramivir adapts itself
to the changes of the H7N9 NA conformation by making
a clockwise twist towards the empty space to interact
with Glu422 instead (while it interacts with Glu274 in the
non-mutated complex). However, this slight change
results in one hydrogen bond loss between peramivir and
the viral NA.
It is observed that in the non-mutated NA/peramivir
complex, residue Arg289 interacts indirectly with peramivir
via two other residues Glu273 and Glu274 serving as inter-
mediate bridges. In contrast, those interaction-mediated
hydrogen bonds are not present in the mutated complex.
When the mutation R289K occurs, the residues Glu273
and Glu274 change their conformations and interact only
with Lys289 without perturbing peramivir (Figure 1B),
causing a decrease in the binding affinity with the
inhibitor.
Our results show that interaction of the H7N9 NA and
zanamivir is the most surprising among the three NA/
inhibitors complexes because the mutation R289K pro-
duces a direct contact between zanamivir and the substi-
tuted Lys289. In the non-mutated NA/zanamivir complex,
besides two polar contacts with Glu273 and Glu274 (as
similar in the non-mutated complex of oseltamivir or
peramivir), the residue Arg289 interacts with a third resi-
due Tyr401. The bulky residue Tyr401 with its planar aro-
matic ring serves as an obstruction preventing the
contact between zanamivir and Arg289 (Figure 1C).
When the smaller residue Lys substitutes Arg, subse-
quently causing the conformational change of Tyr401, this
obstruction seems to be alleviated. As a result, zanamivir
is pulled upwards and interacts with the substituted
Lys289. However, changes of zanamivir conformation
make it further distant to the active site residue Arg152
(11.9Å) and lose their native interaction. This causes one
hydrogen bond loss between zanamivir and the NA
protein.
In general, the mutation R289K induced conforma-
tional changes of the H7N9 NA inhibitor-binding pocket.
Neighboring active site residues, i.e. Glu273, Glu274, and
Tyr401 are involved in those steric alterations to compen-
sate for the decrease of either hydrophilicity or size of the
substituted Lys289. The mutation results in the loss of
number of hydrogen bonds between the inhibitor and the
H7N9 NA in 2 out of 3 cases of mutated complexes, i.e.
NA/zanamivir, and NA/peramivir. It is too early to claim
that the interaction observed in this study occur to all
NA proteins of the novel avian influenza A (H7N9) virus,
and these results will require further analysis since they
are subject to specific docking parameters and MD simu-
lation time (i.e. 20 ns in this study) to achieve the optimal
and stable conformations. Also, the results are inter-
preted for the strain A/Hangzhou/1/2013 (H7N9) from
which the mutation has not yet been reported.
Binding-affinity relationships of oseltamivir, zanamivir,
and peramivir with viral neuraminidase proteins of
previous pandemic (H1N1, H5N1) and the current
novel H7N9
To further investigate the binding effectiveness of the
3 NA inhibitors to the novel H7N9 neuraminidase com-
pared to the previous pandemic influenza A viruses
H5N1 and H1N1, we performed molecular docking
experiments using AutoDock 4.2 for these inhibitors (as
ligand) with several available structures of H5N1 and
H1N1 neuraminidases. Their binding affinities (kcal/mol)
are tabulated in Table 3.
Russell et al. shows that difference in oseltamivir-
binding affinity between group-1 (N1) and group-2 (N9)
Table 2 Binding free energy ΔΔG (kcal/mol) of the H7N9
NA/inhibitors complexes
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neuraminidases is not very large [15]. Our results are in
accordance with their observation in the case of oselta-
mivir. Compared to the other two H5N1 and H1N1
neuraminidases in our results, the novel H7N9 NA
interacts with all the three inhibitors with higher bind-
ing energy. This could suggest that even without the
emergence of any mutations, the H7N9 viral susceptibil-
ity to these drugs is lower than the other influenza
viruses. Hence, it might be easier for this novel H7N9
strain to acquire resistance to these drugs.
In addition, based on our study of binding free energy
between the H7N9 NA and the 3 inhibitors, it is likely
Figure 1 Observed conformational changes in the inhibitor-binding site of the non-mutated (left) and mutated (right) complexes of
NA/inhibitors. Neuraminidase inhibitors are presented in colored sticks (oseltamivir: orange, peramivir: blue, zanamivir: yellow), other involved
NA residues are presented in green line, except for residues Arg and Lys (mutation R289K) in magenta color. The grey cartoon-presented
background is the H7N9 NA structure. All the interactions are shown in black dotted line. Oxygen atoms are in red, nitrogens are in blue, and
hydrogens are in white. For simplicity, only hydrogens involved in the interactions are shown. (A) Occupation of the bulky residue Trp292 in the
empty space created by a substituted smaller residue Lys289 (R289K) and the change of N-terminal (yellow) conformation influenced contacts
between oseltamivir and the H7N9 NA binding site. (B) Conformation of peramivir twists (small arrow) towards the empty space, causing it to
interact with Glu422 instead of Glu274. (C) Conformational change of Tyr401 induces interaction between zanamivir and the substituted residue
Lys289. However, this interaction also causes one hydrogen bond loss in total between zanamivir and the H7N9 NA.
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that the novel influenza A (H7N9) virus adopts a higher
probability to acquire resistance to peramivir than the
other two inhibitors. Our MD simulation results also
indicate that at the equilibrium state the interaction
between the H7N9 NA and peramivir is less favorable
than those in complexes of NA/oseltamivir and of NA/
zanamivir since the NA/peramivir complex obtains the
highest binding free energy among the 3 complex asso-
ciations both before and after (-39.02/-37.26 kcal/mol)
the mutation R289K occurs (i.e. NA/oseltamivir:
-49.49/-37.46 kcal/mol and NA/zanamivir: -54.73/-47.24
kcal/mol) as shown in Table 2. In future drug design,
we expect stronger binding inhibitors will overcome the
energy barriers caused by potential mutations of the
novel H7N9 influenza A virus.
Conclusions
Combination of molecular docking and molecular
dynamics simulation demonstrated differential inhibitor-
bindings of the non-mutated and mutated novel H7N9
influenza viral neuraminidase. Mutation R289K-induced
conformational changes that cause the loss of hydrogen
bond chains between the inhibitors and the viral neura-
minidase suggest potential adaptions of the virus itself
for future drug-resistance. While the results are novel for
the A/Hangzhou/1/2013(H7N9) strain, further studies
and analysis of conformational changes in population
level of other strains still needs to be conducted and
experimentally verified.
Methods
Homology modeling of the novel avian influenza A
(H7N9) viral neuraminidase
We used the neuraminidase (NA) sequence of A/Hang-
zhou/1/2013(H7N9) strain from NCBI [24] [Genbank:
AGI60300.1] as our protein target. Examining protein
sequences of available N9 neuraminidase structures in
Protein Data Bank [25], we observed that the novel
H7N9 neuraminidase sequence contains an extra 77
residues at its N-terminus. Therefore, to obtain full-
length 3-dimensional structure of this novel protein,
we applied homology modeling method using I-TAS-
SER [26] for the selected NA sequence (see Additional
file 2).
It was shown that except for the 77-residue region at
the N-terminus, the rest of the target NA H7N9
sequence (residues 78-465) is highly similar to all the
threading templates (95%). To model the 77-residue
N-terminus without any available templates, the I-
TASSER server applied replica-exchange Monte Carlo
simulation method to simulate the folding process of
this region, which contains 2 helices and coils. We
observed that the N-terminal 77-residue region was
not involved in the inhibitor-binding ability of the
H7N9 NA protein; therefore we accepted the best
model from I-TASSER and subsequently applied mole-
cular dynamics (MD) simulation method (see below)
for the whole model to improve its quality and obtain
the optimal conformation.
RMSD calculation of this optimal H7N9 NA structure
and two other wild-type N9 neuraminidases
[PDB:2QWK] (RMSD = 2.27Å) and [PDB:7NN9]
(RMSD = 2.23Å) proved it as a reliable modeled struc-
ture. Hence, we used this optimal conformation of
H7N9 NA for further analysis.
We performed binding site prediction using Site-
Hound [27] for this H7N9 NA structure and cross-vali-
dated the results with other influenza viral NAs [15].
The predicted binding site contains residues Thr144,
Ile145, Asp147, Arg152, Glu274, Arg367, Trp398, Ser399,
Tyr401, Glu422, and Ile424.
Obtain optimal complexes of non-mutated and mutated
H7N9 neuraminidase (NA) with current NA inhibitors
We obtained structures of three NA inhibitors oseltami-
vir [CID:65028], zanamivir [CID:60855], and peramivir
[CID:151164] from PubChem. For all these NA inhibi-
tors, we applied molecular docking method using Auto-
Dock 4.2 [21] to obtain the NA/inhibitor complexes. The
inhibitor was docked as ligand to the active site of the
H7N9 NA. We used the grid spacing of 0.2 for better
accuracy after various docking tests (data not shown). All
available rotatable bonds of each ligand (oseltamivir: 11
bonds, zanamivir: 10 bonds, peramivir: 10 bonds) were
activated to allow full flexibility of the ligand. For each
complex, 100 independent docking experiments were
performed, and the top rank-1 conformation was selected
for further investigation.
Table 3 Predicted binding affinity of three NA inhibitors with the novel H7N9, H5N1, and H1N1 neuraminidases
NA inhibitor Binding affinity (kcal/mol)
Novel H7N9 H5N1 [PDB id] H1N1 [PDB id]
[2HTU] [2HU0] [2HU4] [3TI6] [3B7E] [3TI5]
oseltamivir -7.49 -8.65 -8.30 -8.33 (2.26)* -8.18 (1.82)* -8.28 -8.16
peramivir -7.20 -8.53 (1.6)* -7.35 -7.94 -7.78 -7.81 -7.96
zanamivir -6.33 -7.08 -6.94 -6.71 -6.92 -7.27 (0.69)* -7.32 (0.92)*
* Root Mean Square deviation (RMSD) of the docked complex to the native complex structures
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To improve bound conformations of semi-rigid dock-
ing from AutoDock 4.2, we conducted molecular
dynamics simulations using AMBER 11 force field ff99SB
[28]. A 3-stage dynamic simulation of minimization,
heating, and equilibration under periodic boundary con-
dition was performed for the NA/inhibitor docked com-
plexes. During this process, explicit solvent model was
applied. In the first stage, we used a weak positional
restraint by a 500kcal/molÅ2 force constant for the
whole NA/inhibitor complex of the first 1,000 steps of
minimization to hold it fixed while positions of solvent
and sodium ions were initially minimized. In the next
2,500 steps of minimization, we removed this restraint.
Constant volume was set during the minimization stage.
In the next stage of 20ps heating, we put the restraint on
the system again, but with only 10kcal/molÅ2 to avoid
wild fluctuations within the structure. We heat up the
system from 0K to 300K, and in order to control the tem-
perature we applied Langevin temperature equilibration
scheme. Then, we performed a 20 ns equilibration stage
without the restraints for the whole complex at constant
pressure of 1 atm and at 300K. For both the heating and
equilibration stages, we applied SHAKE to constrain
bonds that involves hydrogen. Finally, we extracted the
lowest energy complexes obtained from the 20 ns equili-
bration above and used them as final bound conforma-
tions of the docked NA/inhibitor complexes for further
analysis.
Binding free energy calculation for associations of H7N9
NA protein and NA inhibitors
We used Molecular Mechanics - Generalized Born Sur-
face Area (MM-GBSA) method implemented in AMBER
11 to calculate the binding free energy for the complex
of NA and NA-inhibitors. Final estimated binding free
energy (ΔΔG kcal/mol) is calculated as ΔΔGbinding =
ΔGcomplex - (ΔGreceptor + ΔGligand).
For effective computational cost, we only performed
the calculation of interaction energy and solvation free
energy of the complex, receptor, and ligand, but ignored
the entropy contribution to these bindings. Therefore,
the free energy (ΔG) of each component (receptor,
ligand, or complex) consists of various potential terms,
i.e. van der Waals, electrostatic energy calculated by
molecular mechanics force field, electrostatic contribu-
tion and nonpolar contribution to the solvation free
energy.
Additional material
Additional file 1: Results of hydrogen bond analysis of the 3 NA/
inhibitor complexes for the whole 20ns MD simulation.
Additional file 2: Homology modeling study of the H7N9 NA
structure from I-TASSER and MD simulation.
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